G. Eric Davis
About G. Eric Davis
G. Eric Davis is Executive Vice President, Chief Legal Officer and Secretary of BioMarin Pharmaceutical (BMRN), having joined the company in March 2004; he is 54 years old . He holds a B.A. in Political Economy from UC Berkeley and a J.D. from the University of San Francisco School of Law, and previously practiced at Paul Hastings LLP with a focus on corporate/securities and M&A matters . Davis is not listed as an executive officer or director of Inozyme Pharma (INZY); INZY’s named executives are Douglas A. Treco (CEO), Sanjay S. Subramanian (CFO), and Matthew Winton (COO), and its board does not include Davis . In the INZY–BioMarin merger, Davis is the designated legal contact in tender/support documents and signed BioMarin’s filings as Chief Legal Officer, underscoring his central role in transaction execution .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| BioMarin Pharmaceutical | EVP, Chief Legal Officer & Secretary; previously General Counsel | 2004–present | Leads global legal, corporate governance, and transactions; legal point for INZY tender offer |
| Paul Hastings LLP | Corporate/Securities attorney; national securities practice committee | 2000–2004 | Advised on M&A, capital markets, strategic alliances across life sciences |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| BioMarin (stockholder communications) | Corporate Secretary contact for Board | Ongoing | Stockholder communications to Board directed “c/o G. Eric Davis” |
Fixed Compensation
- No individual compensation disclosure for Davis was found in BioMarin’s proxy (NEO tables cover CEO/CFO and other NEOs), and INZY does not list Davis as an executive. Company-wide executive pay philosophy at BioMarin emphasizes high variable/at‑risk pay with majority delivered in long-term equity, annual cash incentives tied to financial and development goals, and robust governance (ownership guidelines, clawback, anti-hedging) .
- INZY’s executive base salaries and cash bonus framework are disclosed for its own executives (e.g., 2024 salaries and target bonuses for Treco, Subramanian, Winton), but these do not apply to Davis .
Performance Compensation
BioMarin’s corporate metrics used for executive annual cash incentives (indicative of Davis’ program participation as a senior executive, though his specific payout is not disclosed):
| Metric | Target | Result | Payout Basis |
|---|---|---|---|
| Total Revenue ($M) | $2,810 | $2,841 | 130% component; FX-adjusted GAAP basis |
| Non-GAAP Diluted EPS | $3.15 | $3.29 | EPS component above target with defined adjustments |
| Development Goals | 100% | >100% | Overachievement on pipeline milestones |
Long-term performance equity (company-wide PSUs) paid above target for 2022–2024, driven by core operating margin, strategic goals, and capped RTSR (negative TSR cap) .
Equity Ownership & Alignment
- BioMarin: Executives and directors must meet stock ownership guidelines (CEO 6x salary; directors 5x cash retainer), with prohibitions on short sales, options, hedging, and margin activities; clawback policies maintained .
- INZY: Adopts Dodd‑Frank compliant compensation recovery (clawback) and prohibits hedging/pledging absent extraordinary preapproval, though Davis is not an INZY executive/director .
Employment Terms
- No employment agreement, severance, or change‑in‑control terms for Davis were disclosed in BioMarin’s proxy; INZY employment contracts disclosed pertain to its own executives (Treco, Subramanian, Winton) and do not involve Davis .
Board Governance
- INZY board composition does not include Davis; independence and committee structures are defined with Treco serving as CEO and Chairman, and a Lead Independent Director (Reinaldo Diaz) mitigating combined role concerns .
- Davis serves as BioMarin’s Corporate Secretary (officer), not as a director; thus independence and committee chair roles are not applicable to him at either company. His governance role includes managing stockholder communications to BioMarin’s Board and supporting board/committee operations .
- In the INZY tender/support agreements, Davis is listed as BioMarin’s legal contact, reinforcing his oversight of governance mechanics during the acquisition .
Investment Implications
- Transaction execution capability: Davis’ central legal role in the INZY tender offer (as BioMarin’s CLO) supports smooth deal mechanics (Schedule TO/14D‑9 coordination, tender/support agreements), reducing execution risk for INZY’s sale process .
- Alignment and risk controls: While Davis’ individual compensation is not disclosed, BioMarin’s executive pay governance (ownership guidelines, anti‑hedging/margin, clawback) lowers incentive misalignment/hedging risks commonly flagged by investors .
- Board independence at INZY: With CEO/Chairman combined (Treco) but a Lead Independent Director in place, independence concerns are mitigated structurally; Davis has no dual‑role exposure at INZY given he is neither executive nor director there .
- Data gaps: Lack of Form 4/beneficial ownership disclosures for Davis at INZY (he is not an INZY insider) means no direct insider selling pressure signals tied to him; trading signals should be assessed from INZY insiders and deal timelines rather than Davis-specific filings .
Notes: All compensation and governance references for Davis derive from BioMarin disclosures; INZY disclosures confirm he is not an INZY officer/director. Where company-wide metrics/policies are cited, they indicate framework rather than Davis-specific pay outcomes.